Genzyme Corp.  (GENZ) Trade Now »     Rate GENZ  -  Discuss GENZ  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

GENZ Analysis & Videos »


GENZ: Bull or Bear?

Early Financial Fireworks Hit the Markets; Will the U.S. Emerge the Leader in the Second Half of Year? GENZ

Filed under: Forecasts, Good news, Google (GOOG), Yahoo! (YHOO), Newsletters, McDonald's (MCD), Netflix, Inc. (NFLX), Adobe Systems (ADBE), AutoZone Inc (AZO), Best Buy (BBY), Kroger Co (KR), Chipotle Mexican Grill'A' (CMG), News Corp'B' (NWS), Economic Data, S and P 500, DJIA, Initial Public Offerings, Stocks to Buy, Northrop Grumman (NOC), Genzyme (GENZ), Stock Picks With all the mixed signals driving uncertainty and worry lately, the consensus has been a foggy windshield with no clear direction. We can't even tell if one of the largest bear market rallies in history is fizzling or pausing... Continue reading »

By  Derek And   (+66.14%  risk: conservative)  07/02/10

5 comments

FDA, Clinical Trial News: Delcath, Genzyme, Isis Pharma GENZ

73%

After the market close, Delcath Systems (NASDAQ:DCTH) reported that its pivotal Phase 3 National Cancer Institute (NCI)-led multi-center study met the primary endpoint for the regional delivery of melphalan to the liver for metastatic melanoma patients with un-removable tumors. DCTH expects to initiate its rolling NDA submission with the FDA in the next 30 days, is scheduled to present the results at ASCO on June 5, and expects to file for CE Mark clearance in Europe by year-end. <> <font> The following is a summary of the results from the Company's press release: Comparing treatment with ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/21/10

13 comments

FDA, Clinical Trial News: $ABIO, $GENZ, $KV-A, $SLXP GENZ

73%

<> <font> Shares of ARCA biopharma (NASDAQ:ABIO) are soaring today on news of an issued patent that includes the methods of treating heart failure patients with Gencaro (bucindolol) based on genetic testing. ABIO also reported that it has submitted a revised pivotal study protocol to the FDA on 3/25/10 under the SPA process and could begin the study in approximately one year, contingent upon the FDA response and adequate funding. </font> <> <font> Shares of Genzyme (NASDAQ:GENZ) are rebounding today following a drop of approximately 10% for the week on news earlier this week that the FDA w... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  03/26/10

161 comments

Genzyme: Unconvincing Rally GENZ

Filed under: Stocks to Sell, Genzyme (GENZ) Not all of my stock picks work out. I first wrote about Genzyme Corp. (GENZ) on June 19, 2009, at a price of $55.02. In the fall 2009, Genzyme's technicals had deteriorated to the point that the stock chart formed a bear hug: a bearish pattern, and I noted at that time, I thought that the prudent stance in December was to stand aside. <>After falling through key, psychological support at $50, Genzyme's shares found support at/near $47, and have since moved back above $50 and the key 50-day moving average. However, the rally has been less than impressi... Continue reading »

By  Joseph Lazzaro   (+9.57%  risk: moderate)  03/02/10

1 comment

BioMed News Bytes: Genzyme, OSI Pharma, Pfizer, Seattle Genetics GENZ

73%

<> On 11/16/09, Genzyme (NASDAQ: GENZ) announced that it received a Complete Response Letter (CRL) from the FDA for its application to market Lumizyme (alglucosidase alfa) for the treatment of Pompe disease. The FDA stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved. Genzyme believes the other elements of the Lumizyme review, such as the Risk Evaluation and Mitigation Strategy (REMS), the product label, and post-marketing requirements, have been satisfactorily addressed. The FDA co... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  11/16/09

22 comments

Genzyme: Up ahead, an uptrend GENZ

Filed under: Stocks to Buy, Genzyme (GENZ) Genzyne Corp.'s (NASDAQ: GENZ) stock has meandered since the June 19, 2009, Buy recommendation at $55.02, and it appears institutional investors have adopted a wait-and-see stance regarding the company. Even so, I'm reiterating my Buy rating for GENZ. Here's why: Continue reading Genzyme: Up ahead, an uptrend Genzyme: Up ahead, an uptrend originally appeared on BloggingStocks on Mon, 12 Oct 2009 13:10:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments Continue reading »

By  Joseph Lazzaro   (+9.57%  risk: moderate)  10/12/09

1 comment

Genzyme: Robust Growth Prospects at Clearance Sale Prices GENZ

73%

In late July, Genzyme (NASDAQ:GENZ) reported 2Q09 results, including revenue of $1.23 billion (up 5% from $1.17 billion during 2Q08 and up 11% excluding unfavorable currency exchange rates). The Company's Non-GAAP net income (which excludes stock compensation and certain business acquisition items) rose to $232.5 million or $0.85 per diluted share versus $107 million or $0.38 per diluted share in the year-ago period. During 2Q09, Genzyme generated about $281 million in cash (primarily derived from operations) and used about $157 million (primarily for investments in manufacturing facilities... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  08/07/09

14 comments

FDA Calendar Updates: Genzyme FDA Woes Benefit Protalix, Shire GENZ

73%

Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 293 entries as of 7/31/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results. ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  07/31/09

14 comments

FDA, Clinical Trial Updates: GENZ, HGSI, LLY, NGSX GENZ

73%

<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  05/21/09

26 comments

FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson GENZ

73%

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars .   <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/22/09

9 comments

Highly Defensive Index: Opportunities in Healthcare GENZ

73%

The ETF Innovators Highly Defensive Index contains 32 market cap leading companies from the defensive industry groups (A-K) specified below in addition to one position reserved for the SPDR Gold Trust (GLD) as a hedge against long-term inflation and global currency devaluation. Since I last wrote about the index two months ago, Genentech has been acquired by Roche (RHHBY.PK) and the number of securities has been reduced from 40 to 33.   Table with Highly Defensive Index stats and benchmark funds: <> http://biomedreports.com/articles/most-popular/805-highly-def... ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/13/09

11 comments

EXACT Sciences Announces New Management Team GENZ

73%

<> EXACT Sciences Announces New Management Team   Posted by: Mike Havrilla in Untagged   on Mar 18, 2009   <!-- Post Teaser Text --> <> MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences (EXAS) today announced that the company's board of directors has appointed Kevin T. Conroy as president and chief executive, and Maneesh K. Arora as senior vice president and chief financial officer, effective April 2, 2009. Mr. Conroy is joining the company's board of directors immediately. <> Click here for my previous article on EXAS after the Genzyme (GENZ) dea... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  03/18/09

52 comments

Updated Clinical Trial and FDA Decision Calendars GENZ

73%

Updated FDA and Clinical Trial Calendars   By Mike Havrilla on 2/22/09 BioMedReports.com   Below is a summary of updates to the FDA decision calendar since my last article, which includes a total of 90 entries through today:   1.) Nuvo Research (NRIFF.PK) (Canada: NRI.TO) NDA re-submission for Pennsaid - A topical NSAID for arthritis pain/inflammation - along with Paladin Labs (Canada: PLB.TO)   <> 2.) Hemispherx Biopharma (HEB) Ampligen (Poly I: Poly C12U) NDA (three month PDUFA date delay announced 2/18/09 as additional data was submitted w... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  02/22/09

10 comments

Healthcare Investing Trends in '09 and Beyond GENZ

73%

Healthcare Investing Trends for '09 and Beyond <> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector. Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  02/07/09

10 comments

EXACT Sciences Forms Pact with Genzyme GENZ

73%

EXACT Sciences Forms Pact with Genzyme   http://www.etfinnovators.com/2009/01/exact-sciences-forms-pac...   After the market close, EXACT Sciences announced that it formed a strategic pact with Genzyme (GENZ), which represents the grounds for the Board's refusal two weeks ago in response to Sequenom's (SQNM) hostile exchange offer at $1.50 per share in stock. The announcement followed news in the pre-market today that SQNM planned to commence its exchange offer through 3/24/09, valuing EXAS at $41M.   <> However, the GENZ deal included the pur... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  01/28/09

16 comments

People Bullish on GENZ

Derek And Tracked Blogger N/A over 2 years ago	Mike Havrilla Principal 73% over 3 years ago	poire Analyst N/A over 3 years ago
mauskar12 Analyst N/A over 3 years ago	mrkennel Analyst N/A over 3 years ago

People Bearish on GENZ

Joseph Lazzaro Tracked Blogger 43% over 3 years ago

sdepatie Analyst N/A over 3 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.